Mapping translational research in personalized therapeutics: from molecular markers to health policy.

abstract：AIM:Our objective was to describe the association between voriconazole concentrations and CYP2C19 diplotypes in pediatric cancer patients, including children homozygous for the CYP2C19*17 gain-of-function allele. MATERIALS & METHODS:A linear mixed effect model compared voriconazole dose-corrected trough concentrations...

journal_title：Pharmacogenomics

authors： Hicks JK,Crews KR,Flynn P,Haidar CE,Daniels CC,Yang W,Panetta JC,Pei D,Scott JR,Molinelli AR,Broeckel U,Bhojwani D,Evans WE,Relling MV

更新日期：2014-06-01 00:00:00

abstract：AIMS:To study the frequency distribution of cytochrome P450 (CYP) functional genetic variants in five Eurasian populations from the territory of Siberia in Russia. MATERIALS & METHODS:Unrelated healthy Tuvinians, Buryats, Altaians, Yakuts and Russians (n = 87-88) were genotyped for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C...

journal_title：Pharmacogenomics

authors： Makeeva O,Stepanov V,Puzyrev V,Goldstein DB,Grossman I

更新日期：2008-07-01 00:00:00

abstract：AIM:This study evaluated the impact of SULT4A1 gene variation on psychopathology and antipsychotic drug response in Caucasian subjects from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and a replication sample. PATIENTS & METHODS:SULT4A1 haplotypes were determined using SNP data. The r...

journal_title：Pharmacogenomics

authors： Ramsey TL,Meltzer HY,Brock GN,Mehrotra B,Jayathilake K,Bobo WV,Brennan MD

更新日期：2011-04-01 00:00:00

abstract：:A letter in response to: Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics 13(7), 757-762 (2012). ...

journal_title：Pharmacogenomics

authors： Botton MR,Hutz MH,Suarez-Kurtz G

更新日期：2012-11-01 00:00:00

abstract：:The extent of genetic variation found in drug metabolism genes and its contribution to interindividual variation in response to medication remains incompletely understood. To better determine the identity and frequency of variation in 11 phase I drug metabolism genes, the exons and flanking intronic regions of the cyt...

journal_title：Pharmacogenomics

authors： Solus JF,Arietta BJ,Harris JR,Sexton DP,Steward JQ,McMunn C,Ihrie P,Mehall JM,Edwards TL,Dawson EP

更新日期：2004-10-01 00:00:00

abstract：AIM:Several HLA alleles have been associated with antiepileptic drugs (AEDs)-induced cutaneous adverse drug reactions (cADRs) in different populations; however, this has not been investigated in Mexican Mestizos (MM). Thus, the purpose of this preliminary study was to determine the association of HLA class I alleles wi...

journal_title：Pharmacogenomics

authors： Fricke-Galindo I,Martínez-Juárez IE,Monroy-Jaramillo N,Jung-Cook H,Falfán-Valencia R,Ortega-Vázquez A,Alonso-Vilatela ME,López-López M

更新日期：2014-01-01 00:00:00

abstract：:Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...

journal_title：Pharmacogenomics

authors： Vucic EA,Brown CJ,Lam WL

更新日期：2008-02-01 00:00:00

abstract：:Currently, there is sufficient evidence for the use of pharmacogenetic information to optimize medication prescribing, but why has this information not been integrated into the drug prescribing process to improve patient care? A discussion about the major contributing factors that have limited the use of pharmacogenet...

journal_title：Pharmacogenomics

authors： Wiltshire T,Dong OM

更新日期：2018-04-01 00:00:00

abstract：:Hematopoietic stem cell transplantation (HSCT) is a curative treatment for several malignant and nonmalignant disorders. Busulfan (Bu) and cyclophosphamide (Cy) are the most commonly used alkylators in high-dose pretransplant conditioning for HSCT; a treatment that is correlated with drug-related toxicity and relapse....

journal_title：Pharmacogenomics

authors： Hassan M,Andersson BS

更新日期：2013-01-01 00:00:00

abstract：AIM:This national dissemination study evaluated pharmacy students' self-reported overall ability, self-efficacy and attitudes toward applying pharmacogenomics and perceptions of Pharmacogenomics Education Program, a shared pharmacogenomics curriculum. PATIENTS & METHODS:Following a series of train-the-trainer programs...

journal_title：Pharmacogenomics

authors： Lee KC,Hudmon KS,Ma JD,Kuo GM

更新日期：2015-01-01 00:00:00

abstract：AIM:To determine the clinical and genetic predictors of the dipeptidyl peptidase-4 (DPP-4) inhibitor treatment response in Type 2 diabetes mellitus (T2DM) patients. PATIENTS & METHODS:DPP4, WFS1 and KCNJ11 gene polymorphisms were genotyped in a cohort study of 662 T2DM patients treated with DPP-4 inhibitors sitaglipti...

journal_title：Pharmacogenomics

authors： Jamaluddin JL,Huri HZ,Vethakkan SR

更新日期：2016-06-01 00:00:00

abstract：:Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in DPYD. Y186C (rs115232898) and a variant in the 3' untranslated region (rs12132152) are uncommon alleles previously observed in African-Americans. An African-American female underwe...

journal_title：Pharmacogenomics

authors： Sissung TM,Cordes L,Peer CJ,Gandhy S,Redman J,Strauss J,Figg WD

更新日期：2021-01-01 00:00:00

abstract：:PON1 is a key component of high-density lipoproteins (HDLs) and is at least partially responsible for HDL's antioxidant/atheroprotective properties. PON1 is also associated with numerous human diseases, including cardiovascular disease, Parkinson's disease and cancer. In addition, PON1 metabolizes a broad variety of s...

journal_title：Pharmacogenomics

authors： Kim DS,Marsillach J,Furlong CE,Jarvik GP

更新日期：2013-09-01 00:00:00

abstract：AIMS:The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. MATERIALS & METHODS:Towards this end, ABCG2 polymorphisms and expression were assessed in DNA an...

journal_title：Pharmacogenomics

authors： Lemos C,Giovannetti E,Zucali PA,Assaraf YG,Scheffer GL,van der Straaten T,D'Incecco A,Falcone A,Guchelaar HJ,Danesi R,Santoro A,Giaccone G,Tibaldi C,Peters GJ

更新日期：2011-02-01 00:00:00

abstract：:HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and ci...

journal_title：Pharmacogenomics

authors： Galli de Amorim M,Branco G,Valieris R,Tarcitano E,Tojal da Silva I,Ferreira de Araújo L,Noronha Nunes D,Dias-Neto E

更新日期：2019-05-01 00:00:00

abstract：:Referred to as the micromanagers of gene expression, microRNAs (miRNAs) are evolutionarily conserved small noncoding RNAs. Polymorphisms in the miRNA pathway (miR-polymorphisms) are emerging as powerful tools to study the biology of a disease and have the potential to be used in disease prognosis and diagnosis. Detect...

journal_title：Pharmacogenomics

authors： Mishra PJ,Bertino JR

更新日期：2009-03-01 00:00:00

abstract：:The heterogeneous Brazilian population, with European, African and Amerindian ancestral roots is a model case for exploring the impact of population admixture on the frequency distribution of polymorphisms in pharmacogenes, and the design and interpretation of pharmacogenomics trials. Examples drawn from studies carri...

journal_title：Pharmacogenomics

authors： Suarez-Kurtz G,Paula DP,Struchiner CJ

更新日期：2014-02-01 00:00:00

abstract：:Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients & methods: Brazilian kidney recipients were treated with TAC combined with everolimus (n = 178) or mycophenolate sodium (n = 97). The variants in CYP...

journal_title：Pharmacogenomics

authors： Genvigir FDV,Campos-Salazar AB,Felipe CR,Tedesco-Silva H Jr,Medina-Pestana JO,Doi SQ,Cerda A,Hirata MH,Herrero MJ,Aliño SF,Hirata RDC

更新日期：2020-01-01 00:00:00

abstract：:COVID-19 utilizes the ACE2 pathway as a means of infection. Early data on COVID-19 suggest heterogeneity in the severity of symptoms during transmission and infection ranging from no symptoms to death. The source of this heterogeneity is likely multifaceted and may have a genetic component. Demographic and clinical co...

journal_title：Pharmacogenomics

authors： Snyder EM,Johnson BD

更新日期：2020-07-01 00:00:00

abstract：:Large interindividual variation in efficacy and adverse effects of anti-epileptic therapy presents opportunities and challenges in pharmacogenomics. Although the first true association of genetic polymorphism in drug-metabolizing enzymes with anti-epileptic drug dose was reported 10 years ago, most of the findings hav...

journal_title：Pharmacogenomics

authors： Kasperaviciūte D,Sisodiya SM

更新日期：2009-05-01 00:00:00

abstract：AIM:To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome. PATIENTS & METHODS:In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on stati...

journal_title：Pharmacogenomics

authors： Leusink M,Maitland-van der Zee AH,Ding B,Drenos F,van Iperen EP,Warren HR,Caulfield MJ,Cupples LA,Cushman M,Hingorani AD,Hoogeveen RC,Hovingh GK,Kumari M,Lange LA,Munroe PB,Nyberg F,Schreiner PJ,Sivapalaratnam S,de Ba

更新日期：2016-04-01 00:00:00

abstract：:Founded as a spin-off from the University of Vienna in 1999, VBC-GENOMICS Bioscience Research GmbH (LLC) has rapidly gained a strong position within the Austrian biotech scene, based on its success as a service provider in oligonucleotide synthesis and custom sequencing. In research, the company has focused on the dev...

journal_title：Pharmacogenomics

authors： Schmidt WM

更新日期：2004-06-01 00:00:00

abstract：AIM:Association of the brain-derived neurotrophic factor (BDNF) genetic polymorphism rs6265 (Val66Met) with methamphetamine (METH) dependence and METH-induced psychosis was investigated in the Thai population. MATERIALS & METHODS:The rs6265 genotype was determined in 100 male METH-dependent subjects and 102 controls u...

journal_title：Pharmacogenomics

authors： Iamjan SA,Thanoi S,Watiktinkorn P,Nudmamud-Thanoi S,Reynolds GP

更新日期：2015-01-01 00:00:00

abstract：AIMS:Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular...

journal_title：Pharmacogenomics

authors： Blum S,Vardi M,Brown JB,Russell A,Milman U,Shapira C,Levy NS,Miller-Lotan R,Asleh R,Levy AP

更新日期：2010-05-01 00:00:00

abstract：:We report the case of a patient bearing a T315I-mutant chronic myeloid leukemia resistant to nilotinib, successfully treated with omacetaxine and then with dasatinib. After 9 months of nilotinib, the patient achieved a major molecular response but relapsed 3 months later due to the T315I mutation. Because third-genera...

journal_title：Pharmacogenomics

authors： Venton G,Colle J,Mercier C,Fanciullino R,Ciccolini J,Ivanov V,Suchon P,Sebahoun G,Beaufils N,Gabert J,Hadjaj D,Costello R

更新日期：2015-01-01 00:00:00

abstract：AIM:Genetic variants contribute to statins' therapeutic variability. SREBF-SCAP pathway is a key player in lipid homeostasis. Hence, effect of SREBF-SCAP polymorphisms on therapeutic response was studied. PATIENTS & METHODS:Metabolic syndrome patients of either sex were prescribed rosuvastatin 10 mg for 24 weeks. Clin...

journal_title：Pharmacogenomics

authors： Rafeeq MM,Habib HS,Murad HAS,Gari MA,Gazzaz ZJ

更新日期：2018-02-01 00:00:00

abstract：:Pharmacogenomics (PGx) implementation in clinical practice is steadily increasing. PGx uses genetic information to personalize medication use, which increases medication efficacy and decreases side effects. The availability of clinical PGx guidelines is essential for its implementation in clinical settings. Currently,...

journal_title：Pharmacogenomics

authors： Nagy M,Attya M,Patrinos GP

更新日期：2020-11-01 00:00:00

abstract：:Migraine is considered one of the most disabling neurological disorder with a high socioeconomic burden. Pharmacological management includes many classes of drugs which in the most cases, are administrated in polytherapy. The therapeutic scheme of migraineurs is often affected by comorbidities which need concomitant m...

journal_title：Pharmacogenomics

authors： Borro M,Guglielmetti M,Simmaco M,Martelletti P,Gentile G

更新日期：2019-11-01 00:00:00

abstract：:High-throughput data collection using gene microarrays has great potential as a method for addressing the pharmacogenomics of complex biological systems. Similarly, mechanism-based pharmacokinetic/pharmacodynamic modeling provides a tool for formulating quantitative testable hypotheses concerning the responses of comp...

journal_title：Pharmacogenomics

authors： Almon RR,DuBois DC,Piel WH,Jusko WJ

更新日期：2004-07-01 00:00:00

abstract：AIMS:Survivin (SVV) mRNA expression levels in peripheral blood of patients with gastrointestinal malignancies change significantly during the course of treatment. We wanted to scrutinize these findings in patients with esophageal carcinoma and furthermore evaluate whether the detection of mRNA and the change in detecti...

journal_title：Pharmacogenomics

authors： Hoffmann AC,Vallböhmer D,Grimminger P,Metzger R,Prenzel KL,Hoelscher AH,Brabender J

更新日期：2010-03-01 00:00:00